Institutional shares held 54.2 Million
689K calls
345K puts
Total value of holdings $3.86B
$49M calls
$24.6M puts
Market Cap $3.23B
51,316,500 Shares Out.
Institutional ownership 105.59%
# of Institutions 334


Latest Institutional Activity in HAE

Top Purchases

Q4 2024
Raymond James Financial Inc Shares Held: 243K ($15.3M)
Q4 2024
Principal Financial Group Inc Shares Held: 157K ($9.87M)
Q4 2024
Boston Trust Walden Corp Shares Held: 916K ($57.7M)
Q4 2024
Van Eck Associates Corp Shares Held: 39.6K ($2.5M)
Q4 2024
Fisher Asset Management, LLC Shares Held: 712K ($44.8M)

Top Sells

Q4 2024
Retirement Systems Of Alabama Shares Held: 61.1K ($3.85M)
Q4 2024
Fort Washington Investment Advisors Inc Shares Held: 274K ($17.3M)
Q4 2024
Allianz Asset Management Gmb H Shares Held: 37.6K ($2.37M)
Q4 2024
Sg Americas Securities, LLC Shares Held: 1.73K ($109K)
Q4 2024
Victory Capital Management Inc Shares Held: 271K ($17.1M)

About HAE

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.


Insider Transactions at HAE

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
350K Shares
From 19 Insiders
Grant, award, or other acquisition 241K shares
Exercise of conversion of derivative security 109K shares
Sell / Disposition
277K Shares
From 15 Insiders
Payment of exercise price or tax liability 160K shares
Open market or private sale 38.3K shares
Bona fide gift 38.9K shares
Other acquisition or disposition 39.7K shares

Track Institutional and Insider Activities on HAE

Follow HAEMONETICS CORP and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells HAE shares.

Notify only if

Insider Trading

Get notified when an Haemonetics Corp insider buys or sells HAE shares.

Notify only if

News

Receive news related to HAEMONETICS CORP

Track Activities on HAE